JPMorgan reinstated coverage of Emergent BioSolutions with an Underweight rating and no price target. The analyst reinstated ratings, estimates and price targets for the U.S. large cap biotechnology space.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on EBS:
- Emergent BioSolutions still sees 2023 revenue $1B-$1.1B, consensus $1.05B
- Emergent BioSolutions reports Q3 revenue $270.5M, consensus $237.43M
- Emergent BioSolutions Reports Third Quarter 2023 Financial Results
- EBS Earnings Report this Week: Is It a Buy, Ahead of Earnings?
- UPDATE: Emergent BioSolutions to Release Third Quarter 2023 Financial Results and Conduct Conference Call on November 8, 2023